Ameliorating effects of mirtazapine on visceral hypersensitivity in rats with neonatal colon sensitivity

Neurogastroenterology and Motility

Volumn 22, Issue 9, 2010, Pages

  Yin, J ^a   Wang, W ^a   Winston, J H ^a   Zhang, R ^a   Chen, J D Z ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

antidepressant; gastrointestinal motility; irritable bowel syndrome; mirtazapine; visceral hypersensitivity

Indexed keywords

MIRTAZAPINE;

ABDOMINAL PRESSURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON DILATATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; ELECTROMYOGRAM; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRANSIT; MALE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; SENSITIZATION; STOMACH EMPTYING;

ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; COLON; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROMYOGRAPHY; GASTRIC EMPTYING; GASTROINTESTINAL TRANSIT; INTESTINE, SMALL; IRRITABLE BOWEL SYNDROME; MALE; MIANSERIN; RATS; RATS, SPRAGUE-DAWLEY;

EID: 77955446497     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2010.01526.x     Document Type: Article

References (42)

1. Boyce PM, Koloski NA, Talley NJ. Irritable bowel syndrome according to varying diagnostic criteria: are the new Rome II criteria unnecessarily restrictive for research and practice? Am J Gastroenterol 2000 95 : 3176 3183.
2. Hillila MT, Farkkila MA. Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population. Aliment Pharmacol Ther 2004 20 : 339 345.
3. Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther 2003 17 : 643 650.
4. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006 130 : 1480 1491.
5. Camilleri M, Choi MG. Review article: irritable bowel syndrome. Aliment Pharmacol Ther 1997 11 : 3 15.
6. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002 123 : 2108 2131. (Pubitemid 35408332)
7. Stacher G, Christensen J. Visceral hypersensitivity in irritable bowel syndrome: a summary review. Dig Dis Sci 2006 51 : 440 445.
8. Andresen V, Montori VM, Keller J, West CP, Layer P, Camilleri M. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol 2008 6 : 545 555.
9. Cash BD, Chey WD. Advances in the management of irritable bowel syndrome. Curr Gastroenterol Rep 2003 5 : 468 475.
10. Crowell MD, Harris L, Jones MP, Chang L. New insights into the pathophysiology of irritable bowel syndrome: implications for future treatments. Curr Gastroenterol Rep 2005 7 : 272 279.
11. Brandt LJ, Bjorkman D, Fennerty MB et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002 97 : S7 26.
12. Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009 58 : 367 378.
13. Ruhe HG, Huyser J, Swinkels JA, Schene AH. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 2006 67 : 1836 1855. (Pubitemid 46055194)
14. Kent JM. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 2000 355 : 911 918.
15. Olver JS, Burrows GD, Norman TR. Third-generation antidepressants: do they offer advantages over the SSRIs? CNS Drugs 2001 15 : 941 954.
16. Spiller R. Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease. Neurogastroenterol Motil 2007 19 (Suppl. 2 25 31.
17. Crowell MD, Shetzline MA, Moses PL, Mawe GM, Talley NJ. Enterochromaffin cells and 5-HT signaling in the pathophysiology of disorders of gastrointestinal function. Curr Opin Investig Drugs 2004 5 : 55 60.
18. Talley NJ. Review article: 5-hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: clinical implications. Aliment Pharmacol Ther 1992 6 : 273 289.
19. Thomas SG. Irritable bowel syndrome and mirtazapine. Am J Psychiatry 2000 157 : 1341 1342.
20. Al-Chaer ED, Kawasaki M, Pasricha PJ. A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development. Gastroenterology 2000 119 : 1276 1285.
21. Winston J, Shenoy M, Medley D, Naniwadekar A, Pasricha PJ. The vanilloid receptor initiates and maintains colonic hypersensitivity induced by neonatal colon irritation in rats. Gastroenterology 2007 132 : 615 627.
22. Yilmaz I, Sezer Z, Kayir H, Uzbay TI. Mirtazapine does not affect pentylenetetrazole- and maximal electroconvulsive shock-induced seizures in mice. Epilepsy Behav 2007 11 : 1 5.
23. Kakui N, Yokoyama F, Yamauchi M et al. Anxiolytic-like profile of mirtazapine in rat conditioned fear stress model: functional significance of 5-hydroxytryptamine 1A receptor and alpha1-adrenergic receptor. Pharmacol Biochem Behav 2009 92 : 393 398.
24. Sallam HS, Oliveira HM, Gan HT, Herndon DN, Chen JD. Ghrelin improves burn-induced delayed gastrointestinal transit in rats. Am J Physiol Regul Integr Comp Physiol 2007 292 : R253 7.
25. Scarpignato C, Capovilla T, Bertaccini G. Action of caerulein on gastric emptying of the conscious rat. Arch Int Pharmacodyn Ther 1980 246 : 286 294.
26. Guthrie E, Barlow J, Fernandes L et al. Changes in tolerance to rectal distension correlate with changes in psychological state in patients with severe irritable bowel syndrome. Psychosom Med 2004 66 : 578 582.
27. Bixquert-Jimenez M, Bixquert-Pla L. [Antidepressant therapy in functional gastrointestinal disorders]. Gastroenterol Hepatol 2005 28 : 485 492.
28. Jones R, Latinovic R, Charlton J, Gulliford M. Physical and psychological co-morbidity in irritable bowel syndrome: a matched cohort study using the General Practice Research Database. Aliment Pharmacol Ther 2006 24 : 879 886.
29. Clouse RE, Lustman PJ. Use of psychopharmacological agents for functional gastrointestinal disorders. Gut 2005 54 : 1332 1341.
30. Castle MZ, Silk DB, Libby GW. Review article: the rationale for antidepressant therapy in functional gastrointestinal disorders. Aliment Pharmacol Ther 2004 19 : 969 979.
31. Hayee B, Forgacs I. Psychological approach to managing irritable bowel syndrome. BMJ 2007 334 : 1105 1109.
32. Tack J, Broekaert D, Fischler B, Van Oudenhove L, Gevers AM, Janssens J. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 2006 55 : 1095 1103.
33. Creed F, Fernandes L, Guthrie E et al. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003 124 : 303 317. (Pubitemid 36169247)
34. de Boer TH, Nefkens F, van Helvoirt A, van Delft AM. Differences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan. J Pharmacol Exp Ther 1996 277 : 852 860.
35. Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995 109 : 40 52.
36. Whitehead WE, Holtkotter B, Enck P et al. Tolerance for rectosigmoid distention in irritable bowel syndrome. Gastroenterology 1990 98 : 1187 1192.
37. Bouin M, Plourde V, Boivin M et al. Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology 2002 122 : 1771 1777.
38. Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychopharmacol 1995 10 (Suppl. 4 37 45.
39. Kim SW, Shin IS, Kim JM et al. Mirtazapine for severe gastroparesis unresponsive to conventional prokinetic treatment. Psychosomatics 2006 47 : 440 442.
40. Choung RS, Cremonini F, Thapa P, Zinsmeister AR, Talley NJ. The effect of short-term, low-dose tricyclic and tetracyclic antidepressant treatment on satiation, postnutrient load gastrointestinal symptoms and gastric emptying: a double-blind, randomized, placebo-controlled trial. Neurogastroenterol Motil 2008 20 : 220 227.
41. Gorard DA, Libby GW, Farthing MJ. 5-Hydroxytryptamine and human small intestinal motility: effect of inhibiting 5-hydroxytryptamine reuptake. Gut 1994 35 : 496 500.
42. Gorard DA, Libby GW, Farthing MJ. Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther 1994 8 : 159 166.